Molecular events in uterine cervical cancer

Sexually Transmitted Infections

Volumn 74, Issue 2, 1998, Pages 101-109

  Southern, Shirley A ^a   Herrington, C Simon ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Aetiology; Carcinoma; Cervix; Molecular biology; Papillomavirus

Indexed keywords

ALPHA INTERFERON; CATENIN; COTININE; CYCLIN D1; CYCLIN DEPENDENT KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GENE PRODUCT; GLUCOCORTICOID; HLA ANTIGEN; LEUKOREGULIN; MESSENGER RNA; NICOTINE; PROTEIN P53; RETINOBLASTOMA PROTEIN; STEROID HORMONE; UVOMORULIN; VIRUS PROTEIN;

CARCINOGENESIS; CELL CYCLE; CIGARETTE SMOKING; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS GENE; VIRUS INFECTION; WART VIRUS;

EID: 0031977294     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.74.2.101     Document Type: Review

References (139)

1. Herrington CS. Human papillomaviruses and cervical neoplasia. I: Virology, classification, pathology and epidemiology. J Clin Palhol 1994;47:1066-72.
2. Herrington CS. Human papillomaviruses and cervical neoplasia., II: Interaction with other factors. J Clin Pathol 1995; 48:1-6.
3. Pfister H, Fuchs PG. Papillomaviruses: particles, genome organisation and proteins. In: Syrjänen K, Gissmann L, Koss LG, eds. Papillomaviruscs and hitman disease. Berlin: Springer-Verlag 1987:1-18.
4. Herrington CS. Control of human papillomavirus replication: implications for squamous neoplasia. J Pathol 1996;178:237-8.
5. Thierry F. Proteins involved in the control of HPV transcription. Papillomavirus Report 1993;4:27-32.
6. Doorbar J, Ely S, Sterling J, et al. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991;352:824-7.
7. Banks L, Matlashewski G. Cell transformation and the HPV E5 gene. Papillomavirus Rep 1993;4:1-4.
8. Stoler MH, Rhodes CR, Whitbeck A, et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23:117-28.
9. Jacobs MV, Snijders PJF, van den Brule AJC, et al. A general primer GP5+/GP6+ mediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
10. Bauer HM, Greer CE, Manos MM. Determination of genital human papillomavirus infection by consensus polymerase chain reaction amplification. In: Herrington CS, McGee JO'D, eds. Diagnostic molecular pathology: a practical approach. Vol 2. Oxford: Oxford University Press, 1992:131-51.
11. Coggin JR, zur Hausen H. Workshop on papillomaviruses and human cancer. Cancer Res 1979;39:545-6.
12. Van Ranst MA, Tachezy R, Delius H, et al. Taxonomy of the human papillomaviruses. Papillomavirus Report 1993;4:61-5.
13. Chan S-Y, Delius H, Halpern AL, et al. Analysis of genomic sequences of 95 papillomavirus types:uniting typing phylogeny and taxonomy. J Virol 1995;69:3074-83.
14. Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71:2463-72.
15. Stoppler MC, Ching K, Stoppler H, et al. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996;70:6987-93.
16. Los Alamos National Laboratory HPV sequence database. Internet address: http://hpv-web.lanl.gov
17. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
18. Aziz DC, Perre F, Robitaille J, et al. Human papillomavirus testing in the clinical laboratory. I: Squamous lesions of the cervix. J Gynecol Surg 1993;9:1-7.
19. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer - a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
20. Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
21. Remmink AJ, Walboomers JMM, Helmerhorst TJM, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease - natural history up to 36 months. Int J Cancer 1995;61:306-11.
22. Park TW, Richart RM, Sun XW, et al. Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. J Natl Cancer Inst 1996;88:355-8.
23. Schneider A, Koutsky LA. Natural history and epidemiological features of genital HPV infection. IARC Sci Publ 1992;119:25-52.
24. Popescu NC, DiPaolo JA. Preferential sites for viral integration on mammalian genome. Cancer Genet Cytogenet 1989; 42:157-71.
25. Zimonjic DB, Popescu ND, DiPaolo JA. Chromosomal organization of viral integration sites in human papillomavirus - immortalized human keratinocyte cell lines. Cancer Genet Cytogenet 1994;72:39-43
26. Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6 E7 open reading frames. Virology 1987;161:259-61.
27. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA 1992;89:3159-63.
28. Frattini MG, Lim HB, Laimins LA. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc Natl Acad Sci USA 1996;93:3062-7.
29. Kessis TD, Connolly DC, Hedrick L, et al. Expression of HPV 16 E6 or E7 increase integration of foreign DNA. Oncogene 1996;16:427-31.
30. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 1995;92:1654-8.
31. Berumen J, Casas L, Segura E, et al. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to retention of the E1 E2 genes. Int J Cancer 1994;56:640-5.
32. Berumen J, Unger E, Casas L, et al. Amplification of human papillomavirus types 16 and 18 in cervical cancer. Hum Pathol 1995;26:676-81.
33. Von Knebel-Doeberitz M, Rittmuller C, Aengeneyndt F, et al. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells - consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994;68:2811-21.
34. Crook T, Morgenstein J, Crawford L, et al. Continued expression of HPV16 E7 protein is required for maintenance of the transformed phenotype of cells transformed by HPV16 plus EJ-ras. EMBO J 1989;8:513-9.
35. Kyo S, Klumpp DJ, Inoue M, et al. Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells. J Gen Virol 1997;78:401-11.
36. Yang YF, Tsao YP, Yin CS, et al. Overexpression of the protooncogene c-jun in association with low risk type-specific human papillomavirus infection in condyloma acuminata. J Med Virol 1996;48:302-7.
37. Kaur P, McDougall JK, Cone RC. Immortalisation of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames. J Gen Virol 1989;70:1261-6.
38. Hawley-Nelson P, Vousden KH, Hubbert NL, et al. HPV16 E6 and E7 proteins cooperate to immortalise human foreskin keratinocytes. EMBO J 1989;8:3905-10.
39. Matlashewski G, Osborn K, Banks L, et al. Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ-ras. Int J Cancer 1988;42:232-8.
40. McCance DJ, Kopan R, Fuchs E, et al. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci USA 1988;85:7168-73.
41. Rader JS, Golub TR, Hudson JB, et al. In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. Oncogene 1990;5:571-6.
42. Meyers C, Frattini MG, Hudson JB, et al. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992;257:971-3.
43. Bosch FX, Schwarz E, Boukamp P, et al. Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HcLa x fibroblast hybrid cells. J Virol 1990;64:4743-54.
44. Zur Hausen H. Intracellular surveillance of persisting viral infections: human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986;ii:489-91.
45. Arbeit JM, Munger K, Howley PM, et al. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994;68:4358-68.
46. Coussens LM, Hanahan D, Arbeit JM. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 1996;149:1899-917.
47. Dyson N, Howley P, Munger K, et al. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
48. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 R6 proteins with p53. Science 1990;248:76-9.
49. Tommasino M, Crawford L. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays 1995;17:509-18.
50. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 1992;66:6237-41.
51. Slebos RJC, Kessis TD, Chen AW, et al. Functional consequences of directed mutations in human papillomavirus E6 proteins - abrogation of p53 mediated cell-cycle arrest correlates with p53 binding and degradation in vitro. Virology 1995;208:111-20.
52. Hall PA, Lane DP. Genetics of growth arrest and cell death: key determinants of tissue homeostasis. Eur J Cancer 1994; 13:2001-12.
53. Gotz C, Wagner P, Issinger OG, et al. p21 WAF 1/CIP 1 interacts with protein kinase CK 2. Oncogene 1996;13:391-8.
54. Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
55. Zerfass K, Schulze A, Spitkovsky D, et al. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 1995;69:6389-99.
56. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 expression in human cervical neoplasia. Mod Pathol 1996;9:418-25.
57. Xiong Y, Kuppuswamy D, Li Y, et al. Alteration of cell cycle kinase complexes in human papillomavirus E6 and E7 expressing fibroblasts precedes neoplastic transformation. J Virol 1996;70:999-1008.
58. Winkler B, Crum CP, Fujii T, et al. Koilocytic lesions of the cervix. The relationship of mitotic abnormalities to the presence papillomavirus antigens and nuclear DNA content. Cancer 1984;53:1081-7.
59. Grana X, Reddy EP. Cell cycle control in mammalian cells: role ot cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-19.
60. Steinmann KE, Pei XF, Stoppler H, et al. Elevated expression and activity of mitotic regulatory proteins in human papillomavirus-immortalized keratinocytes. Oncogene 1994;9:387-94.
61. Pagano M, Pepperkok R, Verde F, et al. Cyclin A is required at two points in the human cell cycle. EMBO J 1992;11:961-71.
62. King RW, Jackson PK, Kirschner MW. Mitosis in transition. Cell 1994;79:563-71.
63. di Leonardo A, Khan SH, Linke SP, et al. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997;57:1013-9.
64. Frattini MG, Hurst SD, Lim HB, et al. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumour suppressor protein. EMBO J 1997;16:318-31.
65. Antinore MJ, Birrer MJ, Patel D, et al. The human papillomavirus type 16 E7 gene product interacts with and transactivates the AP1 family of transcription factors. EMBO J 1996;15:1950-60.
66. Busby-Earle R, Steel CM, Bird CC. Cervical carcinoma: low frequency of allele loss at loci implicated in other common malignancies. Br J Cancer 1993;67:71-5.
67. Atkin NB. Cytogenetics of carcinoma of the cervix uteri: a review. Cytogenet Cell Genet 1997;95:33-9.
68. Steenbergen RDM, Walboomers JMM, Meijer CJLM, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogcne 1996;13:1249-57.
69. Solinas-Toldo A, Durst M, Lichter P. Specific chromosomal imbalances in papillomavirus-transfected cells during progression toward immortality. Proc Natl Acad Sci USA 1997; 94:3854-9.
70. Southern SA, Herrington CS. Interphase karyotypic analysis of chromosomes 11, 17 and X in invasive squamous carcinoma of the cervix: morphological correlation with HPV infection. Int J Cancer 1997;70:502-7.
71. Rader JS, Kamarasova T, Huettner PC, et al. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene 1996;13:2737-41.
72. Kohno T, Takayama H, Hamaguchi M, et al. Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene 1993;8:1825-32.
73. Jones MH, Koi S, Fujimoto I, et al. Allelotype of uterine cancer by analysis of RFLP andmicrosatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer 1994:9:119-23.
74. Karlsen F, Rabbitts PH, Sundresan V, et al. PCR-RFLP studies on chromosome 3p in formaldehyde-fixed, paraffin-embedded cervical cancer tissues. Im J Cancer 1994;58:787-92.
75. Mullokandov MR, Kholodilov NG, Atkin NB, et al. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996;56:197-205.
76. Kaelbling M, Burk RD, Atkin NB, et al. Loss of heterozygosity on chromosome 17p and mutant p53 in HPV-negative cervical carcinomas. Lancet 1992;340:140 2.
77. Park SY, Rang YS, Kim BG, et al. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinomas. Cancer Genet Cytogenet 1995;79:74-8.
78. Bethwaite P, Koreth J, Herrington CS, et al. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical cancer. Br J Cancer 1995;71: 814-8.
79. Hampton GM, Penny LA, Baergen RN, et al. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci USA 1994;91: 6953-7.
80. Hampton GM, Larson AA, Baergen RN, et al. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci USA 1996;93: 6704-9.
81. Heselmeyer K, Schruck E, du Manoir S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1996;93:479-84.
82. Larson AA, Kern S, Sommers RL, et al. Analysis of replication error (RER+) phenotypes in cervical carcinoma. Cancer Res 1996;56:1426-31.
83. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
84. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
85. Anderson S, Shera K, Ihle J, et al. Telomerase activation in cervical cancer. Ant J Pathol 1997;151:25-31.
86. Wigle DT, Mao Y, Grace M. Re: Smoking and cancer of the uterine cervix: hypothesis. Am J Epidemiol 1980;111:125-7.
87. Winkelstein W. Smoking and cervical cancer - current status:a review. Am J Epidemiol 1990;131:945-57.
88. Szarewski A, Jarvis MJ, Sasieni P, et al. Effect of smoking cessation on cervical lesion size. Lancet 1996;347:941-3.
89. Morris HHB, Gatter KC, Sykes G, et al. Langerhans' cells in human cervical epithelium: effects of wart virus infection and intraepithelial neoplasia. Br J Obstet Gynaecol 1983;90: 412-20.
90. Morelli AE, Sananes C, Di PG, et al. Relationship between types of human papillomavirus and Langerhans' cells in cervical condyloma and intraepithelial neoplasia. Am J Clin Pathol 1993;99:200-6.
91. Schiffman MH, Haley NJ, Felton JS, et al. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res 1987;47:3886-8.
92. Waggoner SE, Wang X. Effect of nicotine on proliferation of normal, malignant, and human papillomavirus-transformed human cervical cells. Gynecol Oncol 1994;55: 91-5.
93. Sizemore N, Mukhtar H, Couch LH, et al. Differential response of normal and HPV immortalized ectocervical epithelial cells to B|a|P. Carcinogenesis 1995;16:2413-8.
94. Simons AM, Phillips DH, Coleman DV. Damage to DNA in cervical epithelium related to smoking tobacco. BMJ 1993; 306:1444-8.
95. Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clin Microbiol Rev 1995;8:549-56.
96. Iwasaka T, Yokoyama M, Hayashi Y, et al. Combined herpes simplex virus type 2 and human papillomavirus type 16 or 18 deoxyribonucleic acid leads to oncogenic transformation. Am J Obstet Gynecol 1988;159:1251-5.
97. Hildesheim A, Mann V, Brinton L, et al. Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. Im J Cancer 1991;49:335-40.
98. Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994;83:205-11.
99. Vernon SD, Hart CE, Reeves WC, et al. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 1993;27:133-45.
100. Landers RJ, O'Leary JJ, Crowley M, et al. Epstein-Barr virus in normal, pre-malignant, and malignant lesions of the uterine cervix. J Clin Pathol 1993;46:931-5.
101. Gloss B, Bernard HU, Seedorf K, et al. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J 1987;6:3735-43.
102. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989;70:2227-32.
103. Mittal R, Tsutsumi K, Pater A, et al. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993;81:5-12.
104. Bartholomew JS, Glenville S, Sarkar S, et al. Integration of high-risk human papillomavirus DKA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells. Cancer Res 1997; 57:937-42.
105. Wank R, Tomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-5.
106. Jochmus I, Altmann A. Immune response to papillomaviruses: prospects of an anti-HPV vaccine. Papillomavirus Report 1993;4:147-51.
107. Apple RJ, Erlich HA, Klitz W, et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-62.
108. Odunsi K, Terry G, Ho L, et al. Association between HLA DQB1*03 and cervical intraepithelial neoplasia. Mol Med 1995;1:161-71.
109. Connor ME, Stern P. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990;46:1029-34.
110. Duggan-Keen M, Keating PJ, Cromme FV, et al. Alterations in major histocompatibility complex expression in cervical cancer: possible consequences for immunotherapy. Papillomavirus Rep 1994;5:3-9.
111. Glew SS, Duggan-Keen M, Cabrera T, et al. HLA Class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 1992;52:4009-16.
112. Glew SS, Connor ME, Snijders PJ, et al. HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. Eur J Cancer 1993;29A:1963-70.
113. Schneider A, Kay S, Lee HM. Immunosuppression as a high risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 1983;27:220-4.
114. Johnson JC, Burnett AF, Willet GD, et al. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol 1992;79:321-7.
115. Spinillo A, Tenti P, Zappatore R, et al. Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection. Gynecol Oncol 1993;48:210-3.
116. Woodworm CD, Lichti U, Simpson S, et al. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 1992;52: 456-63.
117. Braun L, Durst M, Mikumo R, et al. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection. Mol Carcinog 1992;6:100-11.
118. Leechanachai P, Banks L, Moreau F, et al. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992;7:19-25.
119. Wilding J, Vousden KH, Soutter WP, et al. E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papillomavirus transfected keratinocytes. Cancer Res 1996; 56:5285-92.
120. Walboomers JMM, Meijer CJLM. Do HPV negative cervical carcinomas exist? J Pathol 1997;181:253-4.
121. Burger MPM, Hollema H, Pieters WJLM, et al. Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Br J Cancer 1996;73:831-6.
122. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogens 1991;6:873-5.
123. Crook T, Wrede D, Tidy JA, et al. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 1992;339:1070-3.
124. Fujita M, Inoue M, Tanizawa O, et al. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992; 52:5323-8.
125. Paquette RL, Lee YY, Wilczynski SP, et al. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 1993;72:1272-80.
126. Hgan HYS, Tsao SW, Liu SS, et al. Abnormal expression and mutation of p53 in cervical cancer a study at protein, RNA and DNA levels. Genitourin Med 1997;73:54-8.
127. Crook T, Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992;11:3935-10.
128. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
129. Kurzrock R, Stella Ku MS, Talpaz M. Abnormalities in the PRAD 1 (cyclin. D1/BCL 1) oncogene are frequent in cervical and vulval squamous cell lines. Cancer 1995;75:584 90.
130. Shroyer KR. Human papillomavirus and endocervical adenocarcinoma. Hum Pathol 1993;24:119-20.
131. Duggan MA, McGregor SE, Benoit JL, et al. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum Pathol 1995;26:319-25.
132. Young FI, Ward LM, Brown LJR. Absence of human papillomavirus in cervical adenocarcinoma determined by in situ hybridisation. J Clin Pathol 1991;44:340-1.
133. Tase T, Okagaki T, Clark BA, et al. Human papillomavirus types and localisation in adenocarcinoma and adenosquamous carcinoma of the uterine cervix: a study by in situ hybridisation. Cancer Res 1988;48:993-8.
134. Tase T, Okagaki T, Clark BA, et al. Human papillomavirus DNA in adenocarcinoma in situ and microinvasive adenocarcinoma of the uterine cervix and coexisting cervical squamous intraepithelial neoplasia. Int J Gynecol Pathol 1989;8:8-17.
135. Cooper K, Herrington CS, Lo ES-F, et al. Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma. J Clin Pathol 1992;45:382-4.
136. Samaratunga H, Cox N, Wright RG. Human papillomavirus DNA in glandular lesions of the uterine cervix. J Clin Pathol 1993;46:718-21
137. Higgins GD, Phillips GE, Smith LA, et al. High prevalence of human papillomavirus transcripts in all grades of cervical intraepithelial glandular neoplasia. Cancer 1992;70: 136-46.
138. Parker MF, Arroyo GF, Geradts J, et al. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol 1997;64:242-51.
139. Abeler VM, Holm R, Nesland JM, et al. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer 1994;73:672-7.